Table 1.
Baseline characteristics of the study population before and after PSW matching.
| Before PSW | After PSW | |||||
|---|---|---|---|---|---|---|
| Statin Users (n = 771) |
Nonstatin Users (n = 1709) |
ASMD | Statin Users (n = 635) |
Nonstatin Users (n = 1601) |
ASMD | |
| Age (years) | 33.81 ± 5.03 | 32.89 ± 5.67 | 0.1713 | 33.42 ± 4.72 | 33.1 ± 5.33 | 0.0645 |
| Male, n (%) | 300 (38.91) | 990 (57.93) | 0.3876 | 289 (45.56) | 850 (53.08) | 0.1509 |
| Urb, n (%) | 0.1439 | 0.0493 | ||||
| Urban | 221 (28.66) | 431 (25.22) | 180 (28.36) | 416 (25.96) | ||
| Suburban | 257 (33.33) | 519 (30.37) | 196 (30.98) | 495 (30.94) | ||
| Rural | 293 (38.00) | 759 (44.41) | 258 (27.19) | 690 (43.10) | ||
| Occupation, n (%) | 0.1245 | 0.0958 | ||||
| Dependent | 80 (10.38) | 230 (13.46) | 72 (11.32) | 202 (12.62) | ||
| Civil servants | 20 (2.59) | 47 (2.75) | 15 (2.37) | 43 (2.68) | ||
| Nonmanual worker | 230 (29.83) | 444 (25.98) | 181 (28.37) | 436 (27.26) | ||
| Manual worker | 256 (33.20) | 549 (32.12) | 202 (31.85) | 514 (32.10) | ||
| Other | 185 (23.99) | 439 (25.69) | 163 (25.83) | 406 (25.34) | ||
| Income (NTD), n (%) | 0.2232 | 0.0777 | ||||
| Dependent | 80 (10.38) | 230 (13.46) | 72 (11.32) | 202 (12.62) | ||
| <17,280 | 219 (28.40) | 556 (32.53) | 195 (30.70) | 513 (32.08) | ||
| 17,280–21,008 | 156 (20.23) | 374 (21.88) | 136 (21.52) | 338 (21.13) | ||
| 21,009–33,229 | 187 (24.25) | 336 (19.66) | 136 (21.52) | 328 (20.48) | ||
| >33,300 | 129 (16.73) | 213 (12.46) | 95 (14.94) | 219 (13.69) | ||
| Comorbidities, n (%) | ||||||
| Atrial fibrillation | 0 (0.00) | 3 (0.18) | 0.0593 | 0 (0.00) | 4 (0.23) | 0.0674 |
| Chronic pulmonary disease | 20 (2.59) | 35 (2.05) | 0.0363 | 15 (2.30) | 32 (1.97) | 0.0228 |
| Connective tissue disease | 94 (12.19) | 140 (8.19) | 0.1325 | 66 (10.42) | 148 (9.27) | 0.0386 |
| Diabetes mellitus | 299 (38.78) | 185 (10.83) | 0.6841 | 135 (21.34) | 259 (16.15) | 0.1332 |
| Heart failure | 39 (5.06) | 96 (5.62) | 0.0249 | 28 (4.43) | 84 (5.23) | 0.0370 |
| Hypertension | 582 (75.49) | 1019 (59.63) | 0.3438 | 435 (68.62) | 1013 (63.29) | 0.1125 |
| Liver cirrhosis | 3 (0.39) | 29 (1.70) | 0.1290 | <3 (<0.45) | 22 (1.36) | 0.1290 |
| Peripheral arterial disease | 7 (0.91) | 26 (1.52) | 0.0560 | 4 (0.65) | 21 (1.31) | 0.0674 |
| Polycystic kidney disease | 5 (0.65) | 22 (1.29) | 0.0653 | 9 (1.39) | 18 (1.13) | 0.0234 |
| Charlson comorbidity index, | 2.25 ± 1.1 | 1.88 ± 0.98 | 0.3592 | 1.99 ± 0.91 | 1.94 ± 0.96 | 0.0580 |
| Medications, n (%) | ||||||
| ACEi/ARB | 438 (56.81) | 592 (34.64) | 0.4565 | 287 (45.21) | 634 (39.58) | 0.1141 |
| Other anti-HTN | 598 (77.56) | 845 (49.44) | 0.6107 | 398 (62.76) | 900 (56.24) | 0.1331 |
| Aspirin/Plavix | 64 (8.30) | 58 (3.39) | 0.2103 | 30 (4.81) | 58 (3.63) | 0.0586 |
| Insulin | 151 (19.58) | 73 (4.27) | 0.4862 | 64 (10.12) | 111 (6.96) | 0.1131 |
| OHA | 123 (15.95) | 49 (2.87) | 0.4599 | 50 (7.81) | 73 (4.59) | 0.1339 |
| No. of outpatient visits in the previous year | 33.68 ± 14.70 | 29.51 ± 12.40 | 0.3061 | 31.00 ± 11.69 | 30.32 ± 12.38 | 0.0562 |
| Hospitalizations in the previous year, n (%) | 339 (43.90) | 639 (37.97) | 0.1342 | 257 (40.60) | 620 (38.72) | 0.0384 |
PSW, propensity score weighting; ASMD, absolute standardized mean difference; ACEi/ARB, angiotension converting enzyme inhibitor/angiotension receptor blocker; HTN, hypertension; OHA, oral hypoglycemic agent.